Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Report bias in drug research

A H Bardy1

  • 1National Agency for Medicines, Helsinki, Finland.

Therapie
|July 1, 1996
PubMed
Summary

Selective reporting of clinical trials, known as report bias, can affect drug marketing authorization. Many trials had unreported outcomes, suggesting potential bias unrelated to study design, possibly linked to commercial interests.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Freedom of information.

Lancet (London, England)·1998
Same author

Bias in reporting clinical trials.

British journal of clinical pharmacology·1998
Same author

Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.

Epilepsia·1998
Same author

Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland.

Clinical pharmacology and therapeutics·1994
Same author

Objectively measured tobacco exposure among pregnant women in Finland in 1986 and 1990.

Acta obstetricia et gynecologica Scandinavica·1994
Same author

Objectively measured tobacco exposure during pregnancy: neonatal effects and relation to maternal smoking.

British journal of obstetrics and gynaecology·1993

Area of Science:

  • Pharmacovigilance
  • Clinical Trial Methodology
  • Regulatory Science

Background:

  • Selective reporting of clinical trial outcomes to regulatory authorities can lead to flawed marketing authorization decisions.
  • This practice, termed 'report bias,' poses a significant risk to public health and drug safety.
  • Understanding the extent and nature of report bias is crucial for ensuring the integrity of pharmaceutical regulation.

Purpose of the Study:

  • To investigate the prevalence and characteristics of 'report bias' in clinical drug trials submitted to the Finnish National Agency for Medicines.
  • To determine if incomplete reporting of trial outcomes is associated with specific study designs or phases.
  • To identify potential factors contributing to the selective reporting of clinical trial results.

Main Methods:

  • Retrospective analysis of clinical drug trial data notified to the Finnish National Agency for Medicines between 1987 and 1993.
  • Comparison of reported versus non-reported trial outcomes based on study design, blinding, comparator use, and trial phase (I-IV).
  • Statistical assessment to identify significant differences between reported and non-reported trial groups.

Main Results:

  • Out of 274 clinical drug trials notified, outcomes for 183 (66.8%) were not reported by the end of 1993.
  • No significant differences were found in study design, blinding, comparator use, or phase distribution between reported and non-reported trials.
  • The lack of reporting was not attributable to variations in the investigational plans, suggesting other factors influence reporting.

Conclusions:

  • A substantial proportion of clinical drug trials in Finland had unreported outcomes, indicating a significant issue with report bias.
  • Incomplete reporting appears independent of study design, suggesting that factors such as trial results may influence the decision to report.
  • Findings suggest that trials with results unfavorable to commercial interests may be less likely to be reported, necessitating further investigation and regulatory consideration.

Related Experiment Videos